EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 168 filers reported holding EAGLE PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is 1.44 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $312,779 | +95844.5% | 11,025 | -1.1% | 0.00% | 0.0% |
| Q4 2022 | $326 | -99.9% | 11,144 | +15.1% | 0.00% | 0.0% |
| Q3 2022 | $256,000 | -43.5% | 9,683 | -4.9% | 0.00% | -40.0% |
| Q2 2022 | $453,000 | -6.6% | 10,187 | +4.0% | 0.01% | 0.0% |
| Q1 2022 | $485,000 | +11.0% | 9,797 | +14.1% | 0.01% | 0.0% |
| Q4 2021 | $437,000 | -10.3% | 8,589 | -1.7% | 0.01% | -16.7% |
| Q3 2021 | $487,000 | +27.2% | 8,739 | -2.4% | 0.01% | +50.0% |
| Q2 2021 | $383,000 | +2.7% | 8,953 | +0.1% | 0.00% | -20.0% |
| Q1 2021 | $373,000 | -10.8% | 8,943 | -0.4% | 0.01% | -16.7% |
| Q4 2020 | $418,000 | +4.8% | 8,983 | -4.4% | 0.01% | -25.0% |
| Q3 2020 | $399,000 | +62.9% | 9,397 | +84.3% | 0.01% | +60.0% |
| Q2 2020 | $245,000 | +4.7% | 5,098 | +0.2% | 0.01% | 0.0% |
| Q1 2020 | $234,000 | +13.6% | 5,090 | +48.4% | 0.01% | +25.0% |
| Q4 2019 | $206,000 | – | 3,430 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 112,666 | $1,777 | 0.65% |
| Smith, Graham & Co., Investment Advisors, LP | 273,099 | $4,306,771 | 0.54% |
| BRANDES INVESTMENT PARTNERS, LP | 1,134,363 | $17,888,904 | 0.35% |
| TANG CAPITAL MANAGEMENT LLC | 118,857 | $1,874,375 | 0.26% |
| Virtus Investment Advisers, Inc. | 20,867 | $329,073 | 0.22% |
| DENALI ADVISORS LLC | 32,300 | $509,371 | 0.18% |
| Nebula Research & Development LLC | 11,473 | $180,929 | 0.10% |
| SCOUT INVESTMENTS, INC. | 131,192 | $1,995,430 | 0.05% |
| XTX Topco Ltd | 15,050 | $237,339 | 0.04% |
| PDT Partners, LLC | 19,745 | $311,379 | 0.04% |